Assessment of Anti-Tissue Type Plasminogen Activator Antibodies in Patients With Prosthetic Heart Valve Thrombosis: The ATA Trial
Articolo
Data di Pubblicazione:
2016
Citazione:
Assessment of Anti-Tissue Type Plasminogen Activator Antibodies in Patients With Prosthetic Heart Valve Thrombosis: The ATA Trial / M. Özkan, M. Kalçık, M.O. Gürsoy, L. Öcal, S. Griffini, S. Karakoyun, M. Yesin, S. Gündüz, M.A. Astarcıoğlu, E. Bayam, S. Cerşit, A.Ç. Aykan, M. Cugno. - In: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS. - ISSN 1074-2484. - 21:4(2016 Dec 08), pp. 372-380. [10.1177/1074248415615236]
Abstract:
Thrombolysis is an effective treatment strategy for prosthetic valve thrombosis (PVT). Recombinant tissue-type plasminogen activator (rt-PA) is widely used as a thrombolytic agent. Infusion of rt-PA may trigger the production of anti-tissue plasminogen activator (tPA) antibodies (ATAs). We aimed to evaluate the possible relationship between ATA levels and PVT formation, and the role of baseline ATA levels on outcomes of thrombolytic therapy in patients with PVT.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
echocardiography; heart valve prosthesis; thrombolytic therapy; thrombosis; tissue plasminogen activator
Elenco autori:
M. Özkan, M. Kalçık, M.O. Gürsoy, L. Öcal, S. Griffini, S. Karakoyun, M. Yesin, S. Gündüz, M.A. Astarcıoğlu, E. Bayam, S. Cerşit, A.Ç. Aykan, M. Cugno
Link alla scheda completa: